[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616419":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":19,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":32,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":19,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":19,"overallStatus":51,"whyStopped":19,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":19},{"fullName":5,"class":6},"University of California, San Diego","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Seladelpar","EXPERIMENTAL","Seladelpar 10 mg orally once daily for 52 weeks",[13],"Drug: Seladelpar",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Medical Director of Liver Transplantation, MD","CONTACT","858-246-2181","v1ajmera@health.ucsd.edu",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Veeral Ajmera","Associate Professor Of Clinical, Medicine","100616419","phase-2-seladelpar-in-adult-liver-transplant-recipients-with-ischemic-cholangiopathy-selic-100616419",false,"NCT07305363","Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).","The SELIC Trial Seladelpar for the Treatment of Ischemic Cholangiopathy: An Open-Label, Single-Arm, Investigator-Initiated Study","SELIC","Inclusion Criteria:\n\n1. Adult, age ≥ 18 and \\\u003C 80 years\n2. Diagnosis of ischemic cholangiopathy defined as non-anastomotic biliary strictures confirmed by imaging (ERCP, MRI, percutaneous cholangiogram)\n3. Cholestasis noted by elevated alkaline phosphatase (ALP) and gamma glutamyl transferase (GGT)\n4. Imaging and clinical findings present at least 4 weeks after but within 12 months of liver transplantation\n5. No recent hospitalization within 2 weeks before enrollment to ensure clinical stability\n\nExclusion Criteria:\n\n1. Decompensated liver disease, including but not limited to ascites requiring paracentesis, hepatic encephalopathy, or variceal bleeding.\n2. Pregnancy or breastfeeding.\n3. Current or recent (within 30 days) use of other investigational agents or fenofibrate.\n4. Current or recent (within 30 days) use of cyclosporine\n5. Known hypersensitivity or contraindication to seladelpar or its excipients.\n6. Severe concomitant illness (renal, cardiac, or other systemic condition) that, in the investigator's judgment, would interfere with study participation or interpretation of results.\n7. ALT \\> 150 IU\u002FL.\n8. AST \\> 150 IU\u002FL.\n9. Total bilirubin \\> 5 mg\u002FdL at screening","ALL","18 Years","79 Years",{"count":42,"type":43},10,"ESTIMATED","INTERVENTIONAL",[46],"PHASE2","A prospective, open-label, single-arm, investigator-initiated study (SELIC) to evaluate the efficacy and safety of seladelpar in adult liver transplant recipients with Ischemic cholangiopathy (IC).",[49,50],"Liver Transplant; Complications","Ischemic Cholangiopathy","NOT_YET_RECRUITING","2026-04-03",{"date":54,"type":55},"2026-04-09","ACTUAL",{"date":57,"type":43},"2026-05",{"date":59,"type":43},"2027-12",{"name":5,"class":6}]